Method for separating trophoblastic cells

Abstract

The invention provides a method for separating trophoblastic cells. The method comprises the following steps: obtaining specific antigens expressed on surfaces of various types of trophoblastic cellsaccording to searched documents, and screening the obtained specific antigens; confirming expression of the antigens in the trophoblastic cells through immunohistochemistry, and determining an antibody combination system through immunofluorescence; adding a couplant and an antibody combination into immunizing magnetic beads, and carrying out coupling; collecting a trophoblast sample from a placenta, preparing a sample cell suspension from the sample, and adding the immunizing magnetic beads with a specific antibody for incubation; and washing the immunizing magnetic beads after the incubationstep is completed, thereby obtaining separated purified trophoblastic cells of the placenta. Compared with traditional amniocentesis and chorionic villus sampling, the method has a noninvasive advantage, the material drawing time is relatively early, the risk of infection and abortion is low, and detection results have similar reliability.

Description

technical field [0001] The invention relates to the technical field of cell separation, in particular to a kit for separating trophoblast cells and an application thereof. Background technique [0002] Prenatal diagnosis is one of the important means to reduce birth defects and improve population quality. At present, the main method of clinical prenatal diagnosis is to obtain fetal samples through amniocentesis or umbilical vein puncture for karyotype analysis. This method is invasive, takes a long time to analyze, and the diagnosis time is limited to the second and third trimesters. The acceptance of pregnant women is low and it is not conducive to clinical treatment. [0003] With the development and maturity of high-throughput sequencing technology, large-scale parallel sequencing of fetal cell-free nucleic acid with the help of high-throughput sequencing technology can accurately detect chromosomal aneuploidy. The current non-invasive prenatal diagnosis technology refers...

AI Technical Summary

Problems solved by technology

This method is invasive, takes a long time to analyze, and the diagnosis time is limited to the second and third trimesters. The acceptance of pregnant women is low and it is not conducive to clinical treatment.

[0003] With the development and maturity of high-throughput sequencing technology, large-scale parallel sequencing of fetal cell-free nucleic acid with the help of high-throughput sequencing technology can accurately detect chromosomal aneuploidy. The current non-invasive prenatal diagnosis technology refers to the main It is this kind of technology, but this technology still has certain limitations, which are mainly reflected in three aspects: first, only chromosomal ploidy can be detected in current clinical applications, and the scope of inspection is extremely limited; second, it is affected by placental / maternal ploidy. Chimeric interference can easily lead to false positives. In addition, due to the calculation based on the Z value, it is difficult to completely avoid false negatives. Third, the ability to detect chromosomal deletions is insufficient, and single bases (points, insertions, deletions, etc.) cannot be tested at the same time. Fourth, there are individual differences in the content of fetal free nucleic acid

Images